CO2020016201A2 - Metodos y formulaciones para el tratamiento de obesidad y enfermedades metabolicas relacionadas con la obesidad - Google Patents

Metodos y formulaciones para el tratamiento de obesidad y enfermedades metabolicas relacionadas con la obesidad

Info

Publication number
CO2020016201A2
CO2020016201A2 CONC2020/0016201A CO2020016201A CO2020016201A2 CO 2020016201 A2 CO2020016201 A2 CO 2020016201A2 CO 2020016201 A CO2020016201 A CO 2020016201A CO 2020016201 A2 CO2020016201 A2 CO 2020016201A2
Authority
CO
Colombia
Prior art keywords
obesity
treatment
metabolic diseases
formulations
methods
Prior art date
Application number
CONC2020/0016201A
Other languages
English (en)
Inventor
David Berz
Original Assignee
Valkyrie Pharmaceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valkyrie Pharmaceutics Inc filed Critical Valkyrie Pharmaceutics Inc
Publication of CO2020016201A2 publication Critical patent/CO2020016201A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un análogo de oligonucleótido o polinucleótido que tiene una o más estructuras de la fórmula general: donde B es una base de ácido nucleico de pirimidina o purina, o un análogo de ésta, es usado para el tratamiento de enfermedades metabólicas relacionadas con obesidad.
CONC2020/0016201A 2018-05-24 2020-12-23 Metodos y formulaciones para el tratamiento de obesidad y enfermedades metabolicas relacionadas con la obesidad CO2020016201A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676196P 2018-05-24 2018-05-24
PCT/US2019/033847 WO2019226952A1 (en) 2018-05-24 2019-05-23 Methods and formulations for the treatment of obesity and obesity-related metabolic diseases

Publications (1)

Publication Number Publication Date
CO2020016201A2 true CO2020016201A2 (es) 2021-04-08

Family

ID=68616066

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0016201A CO2020016201A2 (es) 2018-05-24 2020-12-23 Metodos y formulaciones para el tratamiento de obesidad y enfermedades metabolicas relacionadas con la obesidad

Country Status (4)

Country Link
US (1) US11578325B2 (es)
EP (1) EP3807288A1 (es)
CO (1) CO2020016201A2 (es)
WO (1) WO2019226952A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US20090099117A1 (en) * 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007137301A2 (en) * 2006-05-23 2007-11-29 Isis Pharmaceuticals, Inc. Modulation of chrebp expression
CN102625841A (zh) * 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
WO2011048125A1 (en) * 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
EP3400240A2 (en) * 2016-01-08 2018-11-14 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
EP3491001A1 (en) * 2016-07-27 2019-06-05 Roche Innovation Center Copenhagen A/S 5's-lna nucleotides and oligonucleotides
WO2019063792A2 (en) * 2017-09-28 2019-04-04 Secarna Pharmaceuticals Gmbh & Co. Kg OLIGONUCLEOTIDE INHIBITING CHOP EXPRESSION

Also Published As

Publication number Publication date
EP3807288A1 (en) 2021-04-21
US11578325B2 (en) 2023-02-14
WO2019226952A1 (en) 2019-11-28
US20210198668A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
CO2020001879A2 (es) Compuesto heterocíclico y su uso
PE20170300A1 (es) Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
CL2018002991A1 (es) Formulaciones de un inhibidor de lsd1.
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112019011689A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de tnf
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
CO2017007863A2 (es) Ácidos 3-alquil-4-amido-bicíclico [4,5,0] hidroxámico como inhibidores de hdac
CO2020001702A2 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
PE20191351A1 (es) Tratamiento aav de la enfermedad de huntington
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
ECSP20024210A (es) Uso de inhibidores de p38 para reducir la expresión de dux4
CO2022000481A2 (es) Inhibidores de enzimas
ECSP20016817A (es) Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
BR112018072323A2 (pt) unha artificial e conjunto de transferência para unha artificial
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CO2022008664A2 (es) Ácido nucleico antisentido que induce la omisión del exón 50
CO2020016201A2 (es) Metodos y formulaciones para el tratamiento de obesidad y enfermedades metabolicas relacionadas con la obesidad